3 Stocks Moving The Health Care Sector Upward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 74 points (-0.4%) at 17,027 as of Monday, July 21, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 889 issues advancing vs. 2,085 declining with 146 unchanged.

The Health Care sector currently sits down 0.5% versus the S&P 500, which is down 0.4%. A company within the sector that increased today was Alexion Pharmaceuticals ( ALXN), up 0.5%. On the negative front, top decliners within the sector include DaVita HealthCare Partners ( DVA), down 3.4%, Perrigo ( PRGO), down 1.7%, Zimmer Holdings ( ZMH), down 1.3%, Stryker Corporation ( SYK), down 1.0% and Fresenius Medical Care AG & Co. KGaA ( FMS), down 1.0%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Jazz Pharmaceuticals ( JAZZ) is one of the companies pushing the Health Care sector higher today. As of noon trading, Jazz Pharmaceuticals is up $2.43 (1.7%) to $144.72 on light volume. Thus far, 291,231 shares of Jazz Pharmaceuticals exchanged hands as compared to its average daily volume of 824,700 shares. The stock has ranged in price between $140.00-$144.82 after having opened the day at $142.07 as compared to the previous trading day's close of $142.29.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Jazz Pharmaceuticals has a market cap of $8.6 billion and is part of the drugs industry. Shares are up 11.9% year-to-date as of the close of trading on Friday. Currently there are 9 analysts who rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Jazz Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full Jazz Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Medivation Founder Takes Helm at Axovant, Shares Spike

Trevena, Synergy Lead Biotech Movers

Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix